Phlow’s CEO and Co-Founder, Eric Edwards, M.D., Ph.D., joined leaders yesterday from across government and industry in Washington, DC, at the @ASPRgov Industry Summit: U.S. Medical Manufacturing Industrial Development Strategy to discuss one of the most urgent challenges facing U.S. healthcare: strengthening the domestic pharmaceutical supply chain. During yesterday's panel working session on industrial base capacity and resilience, Eric and other leaders focused on identifying critical gaps in America's domestic pharmaceutical supply chain and charting a path toward closing them. Phlow has been building that path since 2020. The ability to manufacture essential medicines on U.S. soil is not a supply chain preference. It is a public health imperative. Through programs like the Strategic Active Pharmaceutical Ingredient Reserve, Phlow is working to ensure that the medicines Americans depend on are stockpiled, secure, and ready when they are needed most. We are committed to this work because the Americans who depend on a resilient medicine supply cannot afford for us not to be. #SAPIR #PharmaceuticalSovereignty #DomesticManufacturing #SupplyChainResilience #Phlow #NationalSecurity #Preparedness

Phlow is heading to the 2026 @dcatorg Global Summit in Sitges, Barcelona, this June. Our Chief Information Officer, Juan Piacquadio, will join industry leaders from @LonzaGroup and @thermofisher on stage for Session II: AI-Driven Drug Development, exploring how artificial intelligence is transforming small-molecule API design and manufacturing, from early route design through commercial supply. At a time when supply chain resilience and digitalization are reshaping how pharma and biopharma companies operate, the organizations that act on these shifts now will define what resilient drug development looks like for the next decade. Juan will share how Phlow is putting AI and advanced process design to work to reduce development timelines, improve scalability, and build more predictable pathways to commercial success. Join us June 10-11 in Barcelona. If you are attending and want to connect, reach out to our team: bit.ly/3PHw4LI. #DCAT #DCATGlobalSummit #AI #DCATGlobal #CDMO #ThoughtLeadership #Digitalization

The future of pharmaceutical manufacturing is being built right now, and we are bringing it to @CPHI_Events North America Conference this June. Phlow is a CDMO purpose-built for pharma and biopharma companies that need a domestic manufacturing partner they can count on. We specialize in small-molecule API manufacturing, from development through commercial supply, helping our partners bring their programs to patients faster and more reliably. If you are looking for a CDMO with the capabilities, capacity, and commitment to support your pipeline, we would love to connect. Find Phlow at booth 624 or book a meeting with our team: bit.ly/3PHw4LI See you in Philadelphia. #CPHI #CPHIAmericas #Phlow #CDMO #Biopharma #DrugDevelopment

Phlow is proud to participate in the 44th Annual @jpmorgan Healthcare Conference next week in San Francisco, California. As a purpose-driven, U.S.-based CDMO, Phlow is redefining how critical medicines are developed and manufactured in America. We provide fully integrated services, from process R&D through commercial-scale production, to help reduce reliance on fragile global supply chains and accelerate time to market for essential therapies. Our CEO, Eric Edwards, MD, PhD, and CFO, Dave Ryan, will meet with industry leaders and partners to explore new opportunities that strengthen U.S. health security and advance a more resilient, reliable pharmaceutical ecosystem. Schedule a meeting with Phlow here:bit.ly/3N5q5Pv #JPM2026 #HealthcareInnovation #PharmaSupplyChain #CDMO #Reshoring #DomesticManufacturing

As we close another year, we reflect on what drives us: innovation, collaboration, and service to others. This season, we’re especially grateful for the brilliant minds and dedicated partners who help bring medicines to life and strengthen the future of how they’re made in America. Your work inspires hope and builds the foundation of a healthier, more resilient nation. From all of us at Phlow, warmest wishes for a joyful holiday season and a bright year ahead. #happyholidays #innovation #service #pharmaceuticalsovereignty

As we look back on 2025, one thing is clear: impact compounds when purpose meets execution. From advancing domestic manufacturing capabilities to strengthening critical partnerships, this year marked meaningful progress toward a more resilient pharmaceutical supply chain in America. Our Phlow Wrapped is a snapshot of the people, progress, and purpose driving our mission forward. Click to view the video. To our employees, partners, and customers, thank you for being part of this journey. Here’s to continuing to create the future of how medicines are made — in America. #PhlowWrapped #ImpactInAction #2025Wrapped

Phlow CEO Eric Edwards, M.D., Ph.D., testified yesterday before the U.S. Senate Special Committee on Aging at a full committee hearing titled “Made in America: Restoring Trust in Our Medicines” on the urgent need to strengthen America’s medicine supply chain and reduce the nation’s dependence on foreign pharmaceutical production. During his testimony, Dr. Edwards emphasized that drug shortages continue to put patients at risk and that restoring domestic API manufacturing is essential to national health infrastructure. He outlined priorities that include predictable federal procurement, multi-year contracts that reward reliability, and sustained investment to rebuild secure American capability. He also noted that progress is possible and that meaningful change can be achieved through coordinated action across government, industry, and healthcare partners. Following the hearing, Dr. Edwards stated, “Phlow remains steadfast in its commitment to work with the federal government, private industry, and other healthcare partners to help restore pharmaceutical resilience in the United States. We have built domestic, state-of-the-art manufacturing infrastructure designed to safeguard reliable access to essential medicines and pharmaceutical ingredients. It stands as proof that we can, and are, creating the future of how medicines are made on American soil.” Click to read the full press release: bit.ly/4pq5WBF Click to view yesterday's hearing: bit.ly/4ibfuOc Learn more about Phlow’s mission to create the future of how medicines are made at phlow-usa.com.

Phlow partnered with @SAP to bring real-time visibility and resiliency to the U.S. medicine supply chain so essential drugs are available when they’re needed most.

“Resiliency isn’t built in common times. It’s built when things go wrong.” Phlow CEO Dr. Eric Edwards shares how @SAP helps reimagine the U.S. medicine supply chain for the future.

This episode of VHHA’s Patients Come First podcast features Dr. Eric Edwards, Chief Executive Officer of @PhlowUSA, a pioneering public benefit pharmaceutical company. Dr Edwards is a keynote speaker at the upcoming Virginia Hospital and Healthcare Leaders Summit scheduled for Nov. 5-7, 2025 in Hot Springs, VA. We cover his work as a clinician and entrepreneur, efforts to boost production of essential medicines in the U.S., and preview his remarks at the upcoming Summit. vhha.com/podcasts/patients-c…

Resiliency isn’t optional. It saves lives. See how @PhlowUSA and @SAP are transforming pharma with AI, cloud data, and end-to-end transparency.

Phlow is honored to be featured in @Inc and @FastCompany as part of The Resiliency Playbook, an inspiring series powered by @SAP that spotlights businesses born to solve a crisis and built for generational impact. The feature — paired with a video interview with our CEO, Eric Edwards — highlights how we’re building a modern foundation for U.S. pharmaceutical development and manufacturing with innovation, security, and AI-driven excellence at the core.  As our CIO, Juan Piacquadio, puts it: “Resiliency is core to our mission because lives depend on it.” Read the article and watch the video to learn more about Phlow’s journey: inc.com/inc-custom-studio/sa… #SupplyChainResilience #AIinPharma #PharmaceuticalManufacturing #CDMO #MadeInUSA #HealthcareSecurity

Today, we pause to honor the courageous men and women who have served and continue to serve our nation. Their sacrifice, leadership, and unwavering dedication remind us of what it means to serve something greater than ourselves.   At Phlow, we are inspired by that same spirit of service – one rooted in protecting and strengthening our nation. As we work to advance U.S. manufacturing and build resilience in America’s medicine supply chain, we do so with deep gratitude for those whose service makes our shared mission possible.   To all who have worn the uniform and those who support them, thank you. Your courage and commitment continue to strengthen the heart of our nation.   #veteransday #phlow #service #gratitude

More than 80% of the most widely used generic medicines in the U.S. depend on active pharmaceutical ingredients (APIs) sourced entirely from outside the United States. As highlighted in @Forbes, this overreliance presents a growing risk to our nation’s health security, access to care, and pharmaceutical affordability. At Phlow, we are working to solve this challenge by building a resilient, fully domestic pharmaceutical manufacturing ecosystem. We've taken bold action to establish U.S.-based supply chains, support national emergency preparedness, and modernize how critical medicines are made. We welcome the growing focus on these issues. The time for investment and bold leadership is now. Phlow is proud to help lead the way through innovation, partnership, and a steadfast commitment to pharmaceutical sovereignty. Read the article: forbes.com/sites/arthurkelle… #Phlow #PharmaceuticalSovereignty #DomesticManufacturing #DrugShortages #HealthcareSecurity

We’re honored to announce that Phlow has been selected as the ketamine sponsor in the @US_FDA Commissioner’s first-ever National Priority Voucher (CNPV) pilot program. The @US_FDA CNPV Pilot Program is designed to accelerate the development and regulatory review of projects that address a U.S. public health crisis, strengthen the U.S. pharmaceutical supply chain, and reduce dependence on foreign manufacturing. With no current domestic ketamine API suppliers, Phlow’s project, in partnership with the U.S. Department of Health and Human Services’ (@HHSGov) Administration for Strategic Preparedness and Response (@ASPRgov), is intended to establish a fully domestic, end-to-end supply chain, from raw materials to finished dosage form, closing a vital gap in national health security. As part of the pilot, Phlow will leverage the voucher to accelerate FDA review timelines, ensuring the timely and resilient availability of this essential medicine through secure U.S.-based production. Our Nation has suffered from multi-year ketamine shortages, with a notable shortage lasting from February 2018 to August 2025. By advancing U.S.-based API production, Phlow is helping to ensure a more secure, transparent, and reliable supply of this critical medicine while reducing the Nation’s dependence on overseas sources. Read the U.S. FDA's press release: fda.gov/news-events/press-an… Read Phlow's press release: phlow-usa.com/phlow-corp-sel…

Heading to @cphi Frankfurt 2025? Connect with the Phlow team to see what’s possible when U.S.-based innovation meets global collaboration. From early development to commercial scale, our advanced facilities and continuous development and manufacturing expertise help pharma and biopharma leaders accelerate programs with speed, quality, and security – all from one U.S. time zone. Connect with our BD team here bit.ly/4qn0tg5/ to schedule a meeting during the event and discover how Phlow can help you bring new medicines to life. #CPHIFrankfurt #PharmaManufacturing #CDMO #USManufacturing #Phlow